Dyne Therapeutics (DYN) stock crashed Tuesday after several key executives departed on the heels of what the company calls “unprecedented” results from its muscular dystrophy treatment.
↑
X
How To Sell Stocks: Long-Term Trend Lines
The biotech company is working on a treatment for a specific group of patients with Duchenne muscular dystrophy. In this disease, the body doesn’t make enough of the dystrophin protein, which helps keep muscles intact. After six months of treatment with Dyne’s drug, dystrophin levels in patients’ muscles were at 3.71% of normal levels.
That’s more than tenfold higher than the 0.3% reached by patients who received Sarepta Therapeutics‘ (SRPT) Exondys 51 in its pivotal study. The Sarepta drug is the standard of care.
Dyne called the results “unprecedented.” But, in a second press release, the company said its chief medical officer, chief commercial officer and chief business officer all stepped down. The CMO, Wildon Farwell, will stay on through the end of the year. CCO Susanna High and CBO Jonathan McNeill are pursing new opportunities.
In morning trades on the stock market today, Dyne Therapeutics stock plummeted more than 33% to 30.46. Shares undercut their 50-day moving average, according to MarketSurge. Dyne has a best-possible IBD Digital Relative Strength Rating which puts its 12-month performance in the leading 1% of all stocks.
Sarepta stock dipped a fraction to 135.61.
Skepticism On Dyne Therapeutics’ Drug
When adjusting for muscle content, dystrophin levels were an average 8.72% of normal levels. That’s greater than new drugs in development today, Dyne Therapeutics said.
Further, Dyne said eight boys who received its DYNE-215 treatment showed functional improvements from six to 12 months. That included how fast they could walk or run 10 meters and how long it took them to rise from the floor, among other measures.
RBC Capital Markets analyst Brian Abrahams doesn’t expect Dyne Therapeutics’ drug to have an impact on Exondys 51 sales.
“We do not see striking dose-dependent functional benefits at about six months compared to placebo, highlighting a possibly unclear benefit of higher dosing with Dyne’s construct,” he said in a report to clients.
Abrahams kept his outperform rating and 181 price target on Sarepta stock.
Follow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Why IBD 50’s Alnylam Just Reversed Its 50% Gain — And BridgeBio Surged
Find The Best Long-Term Investments With IBD Long-Term Leaders
Join IBD Live For Stock Ideas Each Morning Before The Open
IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks
